- Syncona said portfolio company Freeline would disclose further data from a trial of a treatment for haemphilia at a key conference in the Netherlands.

Freeline's second-phase trial was investigating the novel gene therapy, FLT180a.

The date would be presented on 7 February at the annual congress of the European Association for Haemophilia and Allied Disorders at the Hague.

Previously, Freeline had disclosed 66- and 74-week data for a first cohort of two patients who were treated with the lowest study dose.

At 1:09pm: [LON:SYNC] Syncona Ltd share price was -0.25p at 219.75p

Story provided by